Researchers show that the unique birth control formulation worked better than placebo for treating women with premenstrual dysphoric disorder (PMDD).
Researchers from Yale University and other research centers concluded that the oral contraceptive is as effective as selective serotonin reuptake inhibitor (SSRI) antidepressants for preventing PMDD, although the two were not compared against each other.
The newly published study included 450 women with PMDD from across the country.
Yale University's Kimberly Yonkers, MD, who led the research team, reported significant symptom improvement in 48% of women with PMDD in the study who took the oral contraceptive vs. 36% of women taking placebo pills. The women were evaluated over the course of two menstrual cycles.
The findings are published in the September issue of the journal Obstetrics and Gynecology.
"I wouldn't say that this is better that antidepressants, but it does give women and their physicians another treatment option," Yonkers says. "Many women don't want to take SSRIs."
PMDD affects between 3% and 5% of menstruating women and is characterized by severe emotional and/or physical symptoms seen in the days or weeks prior to a women's period. These symptoms are similar to those seen with PMS yet significantly interfere with a woman's work and social functioning and often last longer and are more debilitating.
The study was funded by the oral contraceptive's manufacturer, Berlex Laboratories, which developed it as a treatment for PMDD.
Company spokeswoman Kimberly Schillace tells WebMD that Berlex is hoping to introduce the drug early next year, assuming it gets FDA approval. It will be sold under the brand name Yaz.
"We think Yaz could represent a real shift in the way PMDD is treated," she says. "Up until now women have had to rely on SSRIs to treat these symptoms. We think Yaz could be a terrific new option for women who are also looking for effective contraception."